Clinical Trials Logo

Clinical Trial Summary

This research project aims at better understanding the early biological effects resulting from occupational exposure to complex Polycyclic Aromatic Hydrocarbon (PAH) mixtures. Current biomarkers used as part of biomonitoring campaigns are biomarkers of exposure, not numerous and poorly related to health effects. The aim of this study is thus to improve our understanding of biological consequences of such exposures, both in terms of proteins deregulation, metabolism deregulation and genotoxicity.


Clinical Trial Description

PAHs are ubiquitous pollutants inducing several diseases, among which cancer is the most significant endpoint, with increased incidences of lung, skin, and bladder cancers. PAHs induce genotoxic effects (sister chromatids exchange, micronuclei, DNA damage) but require metabolic activation in humans as indirect-acting carcinogens. Thus, the knowledge of metabolic pathways involved following PAH exposure is critical for understanding and preventing cancer risks. Besides, exposure to PAHs is assumed to induce other adverse health effects (diabetes, inflammation, infertility, cardiovascular disease). Unfortunately, early disease-related biomarkers are still largely unknown and our comprehension about the mechanisms involved is still limited. The rare existing biological limit values either refer to not carcinogenic PAH (pyrene) or detoxification pathways (3-OHBaP for BaP), although new biomarkers reflecting the genotoxic pathway of BaP (TetraolBaP) are now available. There is thus a need for identifying more relevant biomarkers of exposure / effect, and for a better understanding of the biological consequences resulting from PAH exposures as well as the associated metabolic pathways involved. The objectives of the project are : - To better understand and characterize molecular, metabolic and genotoxic impacts resulting from exposure to PAHs and to link such impacts with biological levels of various PAH metabolites, - To study the influence of BaP metabolism (genotoxic versus detoxication pathway) on the differential expression of metabolites / proteins and on genotoxicity endpoints in order to get relevant data for deriving new biological limit values, - To elucidate the associations between omics deregulations due to PAH exposures and activated metabolic pathways, in order to define candidate effect biomarkers for human biomonitoring. The originalities of the project are the following. First, this is a human study performed in real occupational settings on workers exposed to representative PAH mixtures. It is a multidisciplinary approach simultaneously combining up-to-date biomonitoring, omics and cytogenetics analyses, that will give insight into a comprehensive view of metabolic reactions and protein expressions following occupational exposure to PAH mixtures, and allow the identification of the biological processes involved. Carcinogenic BaP metabolites (Tetraol-BaP and 3-OHBaP) will be simultaneously analyzed in order to compare the two main metabolic pathways of BaP. The main steps of the projects will be : - Recruitment of 100 workers differentially exposed to PAH mixtures sampled across two time periods (after weeks of exposure and following 3 weeks without occupational exposure), - Recording of relevant data (work characteristics, jobs / tasks, working experience, number of years of exposure, smoking habits, nutritional intake, co-morbidity), - Toxicological analyses (LC-Fluorescence and GC-MS-MS) of urinary metabolites of several gaseous and particulate PAHs (Naphtalene, Fluorene, Phenanthrene, Pyrene, BaP, BeP, Chrysene, Benzo(b)Fluoranthene, Benzo(k)Fluoranthene, Benzo(a)Anthracene), - Proteomics analyses on blood samples through an enrichment approach for a bottom-up label free quantitative proteomic analysis based LC-HR-MS. Deregulated proteins (DEP) will be identified and the associated protein signature. A gene ontology (GO) analysis will define the groups of biological processes involved, - Untargeted Metabolomics analyses on blood samples in UHPLC-HR-MS, with unsupervised statistical analyses (Principal Component Analysis, Logistic Regressions), identification of relevant metabolites by their comparison to the Human Metabolome database, and advanced molecular networking / spectral library search of LC-MSMS data, - Micronuclei (MN) in buccal cells through the harvesting of buccal cells using a cytobrush, transfer to the lab in a buffer, fixing and staining, automatic counting under fluorescent light. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05679544
Study type Interventional
Source University Hospital, Grenoble
Contact Renaud PERSOONS, PhD, Pharm D
Phone 00 33 4 76 76 51 78
Email RPersoons@chu-grenoble.fr
Status Recruiting
Phase N/A
Start date April 25, 2023
Completion date October 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04528004 - Mechanistic Studies of Nicotinamide Riboside in Human Heart Failure Early Phase 1
Completed NCT04597983 - Effect of 8-week Intake of 2S-hesperidin on Performance, Body Composition and Biochemicals Markers in Amateur Cyclists N/A
Completed NCT03445234 - Blueberries, Bananas, Exercise Recovery N/A
Recruiting NCT04892199 - Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication? Phase 4
Active, not recruiting NCT05070585 - Isothiocyanates and Metabolic Health Phase 1/Phase 2
Not yet recruiting NCT05494151 - Metabolic Substrate of Patients With Myocardial Infarction With and Without Modifiable Cardiovascular Risk Factors
Completed NCT04787952 - Insight Into New Brown Adipose Tissue Activators.
Completed NCT05758857 - Multiple Risk Factor Intervention Trial N/A
Completed NCT02689882 - "Pharmacokinetic Study of Nicotinamide Riboside" Phase 1
Completed NCT01674426 - Pathogenesis of Functional Hypothalamic Amenorrhea N/A
Recruiting NCT06252922 - Diet-Induced Changes in GEnetic Material
Completed NCT06326840 - Clinical Efficacy and Adverse Reactions of Antipsychotic Treatment N/A
Recruiting NCT06345937 - Multiple Risk Factor Intervention Trial (Ms. FIT) N/A
Recruiting NCT06392360 - Betaine, Exercise Performance, and Gut Permeability N/A
Completed NCT04009642 - Cardiac Rest and Stress Metabolism in Patients With Type 2 Diabetes
Withdrawn NCT03515642 - Exercise, Gut Microbiota in Sedentary Adults With Overweight N/A
Recruiting NCT06333184 - Smoothies and Blood Sugars N/A
Not yet recruiting NCT05773183 - Exploring the Relationship Between Androgen Metabolism, Metabolic Disease and Skeletal Muscle Energy Balance in Men
Completed NCT04266665 - Effect of Dexmedetomidine on Brain Homeostasis and Neurocognitive Outcome Phase 4
Completed NCT03697928 - Markers of Carnitine Acetyltransferase (CrAT) Protein Activity and Carnitine Availability